Trial reportPloS one2017
Risk of dementia from proton pump inhibitor use in Asian population: A nationwide cohort study in Taiwan.
Trial report in PloS one, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 47 papers, 5 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
47 citing papers in PubMed, 5 syntheses or guidelines pooled it, 112 citations in OpenAlex.
- Proton Pump Inhibitor Use and Risk of Dementia: An Umbrella Review of Systematic Reviews and Meta-Analyses.Digestive diseases and sciences · 2026Pooled it
- [Clinical Guidelines for Drug-induced Peptic Ulcer, 2020 Revised Edition].The Korean journal of gastroenterology = Taehan Sohwagi Hakhoe chi · 2020Guideline
- Proton pump inhibitors use and dementia risk: a meta-analysis of cohort studies.European journal of clinical pharmacology · 2020Pooled it
- Pooled it
- Pooled it
- Association of Proton Pump Inhibitor Use With Incident Dementia and Cognitive Decline in Older Adults: A Prospective Cohort Study.Gastroenterology · 2023Trial
- Inconsistency in the Association Between Proton Pump Inhibitor Use and Dementia Risk: An Updated Meta-Analysis.Brain sciences · 2026Review
- Long-term proton pump inhibitor use and risk of dementia: a focused review on pantoprazole.Annals of medicine and surgery (2012) · 2025Review
- Causal relationship between proton pump inhibitors and dementia risk: evidence from a Mendelian randomization study.European archives of psychiatry and clinical neuroscience · 2025Article
- Drug-Induced Cognitive Impairment.Drug safety · 2025Review
- Medication Exposure and Risk of Dementia and Alzheimer's Disease.International journal of molecular sciences · 2024Review
- Highly prevalent geriatric medications and their effect on β-amyloid fibril formation.BMC neurology · 2024Article
- Potential Risks Associated With Long-term Use of Proton Pump Inhibitors and the Maintenance Treatment Modality for Patients With Mild Gastroesophageal Reflux Disease.Journal of neurogastroenterology and motility · 2024Review
- Physicians' perceptions and awareness of adverse effects of proton pump inhibitors and impact on prescribing patterns.Frontiers in pharmacology · 2024Article
- Article
- Cumulative Use of Proton Pump Inhibitors and Risk of Dementia: The Atherosclerosis Risk in Communities Study.Neurology · 2023Article
- Article
- Proton Pump Inhibitor Use and Cognitive Function in the Boston Puerto Rican Health Study.The journals of gerontology. Series A, Biological sciences and medical sciences · 2023Article
- Time-Varying Use of Proton Pump Inhibitors and Cognitive Impairment and Dementia: A Real-World Analysis from Germany.Drugs & aging · 2023Article
- Pantoprazole-Induced Bone Loss through Gastrin Secretion: A Stereological Study.BioMed research international · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionConcerns have been raised regarding the potential association between proton pump inhibitor (PPI) use and dementia.
objectiveThis study aimed to examine this association in an Asian population.
methodsPatients initiating PPI therapy between January 1, 2000 and December 31, 2003 without a prior history of dementia were identified from Taiwan's National Health Insurance Research Database. The outcome of interest was all-cause dementia. Cox regression models were applied to estimate the hazard ratio (HR) of dementia. The cumulative PPI dosage stratified by quartiles of defined daily doses and adjusted for baseline disease risk score served as the primary variables compared against no PPI use.
resultsWe analyzed the data of 15726 participants aged 40 years or older and free of dementia at baseline. PPI users (n = 7863; average follow-up 8.44 years) had a significantly increased risk of dementia over non-PPI users (n = 7863; average follow-up 9.55 years) (adjusted HR [aHR] 1.22; 95% confidence interval: 1.05-1.42). A significant association was observed between cumulative PPI use and risk of dementia (P for trend = .013). Subgroup analysis showed excess frequency of dementia in PPI users diagnosed with depression (aHR 2.73 [1.91-3.89]), hyperlipidemia (aHR 1.81 [1.38-2.38]), ischemic heart disease (aHR 1.55 [1.12-2.14]), and hypertension (aHR 1.54 [1.21-1.95]).
conclusionsAn increased risk for dementia was identified among the Asian PPI users. Cumulative PPI use was significantly associated with dementia. Further investigation into the possible biological mechanisms underlying the relationship between dementia and PPI use is warranted.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.